We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-3.02%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$34.5B
AUM Growth
-$708M
(-2%)
Cap. Flow
+$1.23B
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
13.77%
Holding
2,852
New
233
Increased
919
Reduced
1,343
Closed
332
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enphase Energy
ENPH
|
+$342M |
| 2 |
Intel
INTC
|
+$276M |
| 3 |
TSMC
TSM
|
+$237M |
| 4 |
Procter & Gamble
PG
|
+$178M |
| 5 |
JPMorgan Chase
JPM
|
+$170M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$383M |
| 2 |
Occidental Petroleum
OXY
|
+$321M |
| 3 |
PayPal
PYPL
|
+$316M |
| 4 |
S&P Global
SPGI
|
+$145M |
| 5 |
Datadog
DDOG
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.57% |
| 2 | Healthcare | 17.95% |
| 3 | Financials | 9.89% |
| 4 | Industrials | 9.61% |
| 5 | Consumer Discretionary | 7.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
751
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $4.82M | 0.01% |
245,180
+110,700
| +82% | +$2.22M |
|
752
Beam Therapeutics
BEAM
$2.58B
| $4.81M | 0.01% |
101,000
+50,600
| +100% | +$2.89M |
|
|
WNS
753
DELISTED
WNS Holdings
WNS
| $4.8M | 0.01% |
58,697
-46,700
| -44% | -$3.88M |
|
754
Federal Signal
FSS
$7.22B
| $4.8M | 0.01% |
128,700
-13,100
| -9% | -$515K |
|
755
Aldeyra Therapeutics
ALDX
$95.3M
| $4.79M | 0.01% |
897,600
+10,600
| +1% | +$63.6K |
|
756
Phreesia
PHR
$657M
| $4.78M | 0.01% |
187,400
+112,100
| +149% | +$2.8M |
|
757
Northwest Natural Holdings
NWN
$2.16B
| $4.77M | 0.01% |
109,900
-5,800
| -5% | -$294K |
|
|
PACW
758
DELISTED
PacWest Bancorp
PACW
| $4.77M | 0.01% |
210,900
+51,200
| +32% | +$1.38M |
|
|
SHOE
759
Shoe Station Group
SHOE
$410M
| $4.75M | 0.01% |
221,628
-19,700
| -8% | -$451K |
|
|
EGIO
760
DELISTED
Edgio, Inc. Common Stock
EGIO
| $4.75M | 0.01% |
42,704
-13,908
| -25% | -$1.65M |
|
761
Enovix
ENVX
$923M
| $4.74M | 0.01% |
295,314
-270,286
| -48% | -$3.99M |
|
762
Yext
YEXT
$554M
| $4.74M | 0.01% |
1,062,300
+78,700
| +8% | +$365K |
|
763
Lumentum
LITE
$55.4B
| $4.73M | 0.01% |
68,942
-12,200
| -15% | -$1.01M |
|
764
Ecovyst
ECVT
$1.34B
| $4.71M | 0.01% |
558,100
+180,200
| +48% | +$1.71M |
|
765
OptimizeRx
OPRX
$120M
| $4.71M | 0.01% |
317,700
+237,100
| +294% | +$4.69M |
|
|
YELL
766
DELISTED
Yellow Corporation Common Stock
YELL
| $4.69M | 0.01% |
924,300
+57,300
| +7% | +$314K |
|
767
First Trust Cloud Computing ETF
SKYY
$2.78B
| $4.66M | 0.01% |
77,200
+10,800
| +16% | +$747K |
|
768
Codexis
CDXS
$141M
| $4.66M | 0.01% |
768,600
+45,800
| +6% | +$368K |
|
769
International Money Express
IMXI
$386M
| $4.66M | 0.01% |
204,300
-208,100
| -50% | -$4.89M |
|
|
TA
770
DELISTED
TravelCenters of America LLC
TA
| $4.63M | 0.01% |
85,860
-9,100
| -10% | -$453K |
|
771
AbCellera Biologics
ABCL
$1.6B
| $4.63M | 0.01% |
467,700
+420,400
| +889% | +$4.61M |
|
772
Ryder
R
$10.3B
| $4.61M | 0.01% |
61,100
-88,100
| -59% | -$6.7M |
|
773
Blue Owl Capital
OBDC
$5.42B
| $4.61M | 0.01% |
444,300
-340,500
| -43% | -$4.33M |
|
774
Sylvamo
SLVM
$1.5B
| $4.58M | 0.01% |
135,100
-10,100
| -7% | -$383K |
|
775
Arcus Biosciences
RCUS
$3.5B
| $4.57M | 0.01% |
174,800
+40,900
| +31% | +$1.08M |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q3 2022 Portfolio in Review
As of Q3 2022, Two Sigma Advisers held 2,852 positions worth $34.5B, down 2% from $35.3B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Two Sigma Advisers deployed $1.23B of net new capital in Q3 2022, opening 233 new positions and adding to 919 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Netflix, an estimated $383M trimmed.
- Two Sigma Advisers's largest Q3 2022 buy was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
- Two Sigma Advisers added most to Enphase Energy in Q3 2022, an estimated $342M increase.
- Two Sigma Advisers's biggest Q3 2022 reduction was Netflix, cutting an estimated $383M.
- Two Sigma Advisers fully exited S&P Global in Q3 2022, selling an estimated $145M.
- Two Sigma Advisers's ten largest holdings make up 14% of its $34.5B portfolio in Q3 2022.
- Two Sigma Advisers opened 233 new positions and closed 332 in Q3 2022.
- Two Sigma Advisers's portfolio value fell 2% quarter-over-quarter to $34.5B.
Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.